title: [Effect of Madecassoside on Intestinal Mucosal Immunity in Collagen-Induced Arthritis Rats].
abstract: OBJECTIVE
  To explore the changes of intestinal mucosal immunity in collagen-induced arthritis rats and the impact of madecassoside on these changes.
  
  
  METHODS
  Collagen-induced arthritis was established in female Wistar rats. Treatment group was orally administrated madecassoside once daily for consecutive 21 days, while blank control and model groups were orally administered saline at the same volume. The concentrations of sIgA in small intestine content and IFN-γ in small intestinal tissue homogenate were determined by ELISA. The proportions of CD4+ T and CD8+ T in the epithelium and laminar propria of small intestine were detected by flow cytometry, and the ratios of CD4+/CD8+ were calculated. The relative expressions of CD80, CD86, IL-6, IL-12 and Foxp3 mRNA in the small intestine were determined by real-time PCR.
  
  
  RESULTS
  Compared with blank control rats, the concentrations of sIgA in small intestine content and IFN-γ in small intestinal tissue homogenate from model rats were increased, the ratios of CD4+/CD8+ in the epithelium and laminar propria of small intestine were higher and the relative expressions of CD80, CD86, IL-6 and IL-12 mRNA in the small intestine were increased. Madecassoside treatment decreased the concentrations of sIgA in small intestine content and IFN-γ in small intestinal tissue, downregulated the ratios of CD4+/CD8+ in the epithelium and laminar propria and decreased the relative expressions of CD80, CD86, IL-6 and IL-12 mRNA, while upregulated the relative expression of Foxp3 mRNA in the small intestine.
  
  
  CONCLUSIONS
  The intestinal mucosal immune response is enhanced in collagen-induced arthritis rats, the antigen presenting cells are activated abnormally and the immune tolerance is disturbed. Madecassoside treatment can downregulate the intestinal mucosal immune response and benefit for the induction and maintenance of intestinal immune tolerance.
authors.forename: Ting
authors.initials: T
authors.lastname: Wang
authors.forename: Zhi-feng
authors.initials: ZF
authors.lastname: Wei
authors.forename: Yan-nong
authors.initials: YN
authors.lastname: Dou
authors.forename: Yu-feng
authors.initials: YF
authors.lastname: Xia
authors.forename: Yue
authors.initials: Y
authors.lastname: Dai
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000276:immunology*; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen / Q000378:metabolism; D016516:CD4-CD8 Ratio; D005260:Female; D051858:Forkhead Transcription Factors / Q000378:metabolism; D007108:Immune Tolerance; D018928:Immunity, Mucosal / Q000187:drug effects*; D007071:Immunoglobulin A, Secretory / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology; D018664:Interleukin-12 / Q000276:immunology; D015850:Interleukin-6 / Q000276:immunology; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000276:immunology; D007421:Intestine, Small / Q000187:drug effects / Q000276:immunology; D051381:Rats; D017208:Rats, Wistar; D060888:Real-Time Polymerase Chain Reaction; D014315:Triterpenes / Q000494:pharmacology*
chemical_list: D018122:B7-1 Antigen; D051940:B7-2 Antigen; D051858:Forkhead Transcription Factors; C500522:Foxp3 protein, rat; D007071:Immunoglobulin A, Secretory; D015850:Interleukin-6; D014315:Triterpenes; D018664:Interleukin-12; D007371:Interferon-gamma; C093443:madecassoside